Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 6

Exemestane in early breast cancer: a review

Authors Untch M

Published 5 December 2008 Volume 2008:4(6) Pages 1295—1304

DOI https://doi.org/10.2147/TCRM.S4007

Review by Single-blind

Peer reviewer comments 2

Michael Untch1, Christian Jackisch2

1Interdisciplinary Breast Centre, Helios Klinikum Berlin-Buch, University Charité, Berlin, Germany; 2Department of Gynecology/Obstetrics, Klinikum Offenbach GmbH, Offenbach, Germany

Abstract: The adjuvant treatment of women with endocrine-sensitive early breast cancer has been dominated for the last 40 years by tamoxifen. However, the side-effects associated with this therapy have prompted a search for safer and biochemically more selective endocrine agents and led to the development of the third-generation aromatase inhibitors (AIs) anastrozole, letrozole and exemestane. Promising results in advanced disease have paved the way for treating early breast cancer, and AIs are increasingly replacing tamoxifen in the adjuvant setting. Several large, randomized trials with AIs have been completed or are ongoing in women with early-stage breast cancer, documenting the significant impact that these drugs are making on the risk for recurrence of breast cancer. As a result, there is increasing and widespread use of AI therapy for the treatment of early-stage endocrine-responsive breast cancer. This review summarizes the data for exemestane in the adjuvant setting, showing that a switch to exemestane after 2 to 3 years of tamoxifen therapy is associated with a statistically significant survival benefit and is regarded as being sensitive by international and national experts.

Keywords: early breast cancer, adjuvant setting, endocrine-sensitive, tamoxifen, aromatase inhibitor, exemestane, switch, IES 31, NSABP B-33, TEAM

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Dietary education must fit into everyday life: a qualitative study of people with a Pakistani background and type 2 diabetes

Hempler NF, Nicic S, Ewers B, Willaing I

Patient Preference and Adherence 2015, 9:347-354

Published Date: 26 February 2015

Zerumbone-loaded nanostructured lipid carrier induces G2/M cell cycle arrest and apoptosis via mitochondrial pathway in a human lymphoblastic leukemia cell line

Rahman HS, Rasedee A, Abdul AB, Zeenathul NA, Othman HH, Yeap SK, How CW, Wan Nor Hafiza WAG

International Journal of Nanomedicine 2014, 9:527-538

Published Date: 16 January 2014

Analysis of macular cone photoreceptors in a case of occult macular dystrophy

Tojo N, Nakamura T, Ozaki H, Oka M, Oiwake T, Hayashi A

Clinical Ophthalmology 2013, 7:859-864

Published Date: 8 May 2013

Survival of invasive bladder cancer patients, 1998–2009; a central and northern Denmark population-based cohort study

Lund L, Erichsen R, Nørgaard M, Larsen EH, Borre M, Jacobsen J

Clinical Epidemiology 2011, 3:47-51

Published Date: 20 July 2011

Reasons for reoperation after epilepsy surgery: a review based on a complex clinical case with three operations

José F Téllez-Zenteno, Farzad Moien-Afshari, Lizbeth Hernández-Ronquillo, et al

Neuropsychiatric Disease and Treatment 2010, 6:409-415

Published Date: 7 July 2010

Febuxostat in the management of hyperuricemia and chronic gout: a review

Miao Hu, Brian Tomlinson

Therapeutics and Clinical Risk Management 2008, 4:1209-1220

Published Date: 5 December 2008

Pharmacological management of acute bronchiolitis

Melvin Wright, Charles J Mullett, Giovanni Piedimonte

Therapeutics and Clinical Risk Management 2008, 4:895-903

Published Date: 10 October 2008

Update on the treatment of ankylosing spondylitis

Walter P Maksymowych

Therapeutics and Clinical Risk Management 2007, 3:1125-1133

Published Date: 15 January 2008